On June 4, Neurocrine Biosciences rose 5.85% in regular trading, trading at $163.94/share, with trading volume of $89.26 million.

On the news front, RBC Capital Markets recently raised its target price on the company from $180 to $183, maintaining an Outperform rating, citing further upside potential in Crenessity's commercial growth trajectory.

RBC conducted a survey of 35 endocrinologists, which revealed that physicians currently use Crenessity in approximately 23% of relevant patients, with expectations to increase adoption to 37% by year-end. Based on these findings, RBC raised its full-year Crenessity sales estimate from $734 million to $750 million, significantly above the Street consensus of approximately $650 million. The firm noted that this target remains achievable even under more conservative growth assumptions.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)